View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML
HHS/FDA RIN: 0910-AH57 Publication ID: Fall 2017 
Title: ●Definition of the term "Biological Product" 
Abstract:

The Food and Drug Administration (FDA) proposes to amend its regulation that defines biological product to conform to the statutory definition (21 U.S.C. 262) adopted in the Biologics Price Competition and Innovation Act of 2009.

 
Agency: Department of Health and Human Services(HHS)  Priority: Substantive, Nonsignificant 
RIN Status: First time published in the Unified Agenda Agenda Stage of Rulemaking: Proposed Rule Stage 
Major: Undetermined  Unfunded Mandates: No 
EO 13771 Designation: Regulatory 
CFR Citation: 21 CFR 600.3   
Legal Authority: 42 U.S.C. 216    42 U.S.C. 262    42 U.S.C. 263    42 U.S.C. 263a    42 U.S.C. 264    42 U.S.C. 300aa-25    Pub. L. 111–148, title VII, 7002(e), Mar. 23, 2010, 124 Stat. 817    ...   
Legal Deadline:  None
Timetable:
Action Date FR Cite
NPRM  02/00/2018 
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Small Entities Affected: No  Federalism: No 
Included in the Regulatory Plan: No 
RIN Data Printed in the FR: No 
Agency Contact:
Daniel Orr
Regulatory Counsel
Department of Health and Human Services
Food and Drug Administration
Building 51, Room 5199, 10993 New Hampshire Avenue,
Silver Spring, MD 20993
Phone:240 402-0979
Email: daniel.orr@fda.hhs.gov